phase readout
saveNCT07545213: Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
NOT_YET_RECRUITINGupdated 1h ago
community read0 votes
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Phase: PHASE2. Conditions: Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
view source ↗
comments(0)
5-min edit window · permanent after that